Stage I and II non-Hodgkin's lymphoma: Results of combined of THP-COP chemotherapy and radiotherapy

Radiation Medicine - Medical Imaging and Radiation Oncology

Volumn 23, Issue 3, 2005, Pages 156-161

  Ohga, Saiji ^a   Nakamura, Katsumasa ^a   Shioyama, Yoshiyuki ^a   Sasaki, Tomonari ^a   Urashima, Yusuke ^a   Terashima, Hiromi ^b   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Combined modality; Non Hodgkin's lymphoma; Pirarubicin (THP)

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PIRARUBICIN; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HUMAN; LEUKOPENIA; MALE; NONHODGKIN LYMPHOMA; PNEUMONIA; RADIATION DOSE; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 21044434680     PISSN: 02882043     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Bastion Y, Blay JY, Divine M, et al. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival - A groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol, 15: 2945-2953, 1997.
2. Niitsu N, Yamazaki J, Nakayama M, Umeda M. Pirarubicin-induced myocardial damage in elderly patients with non-Hodgkin's lymphoma. Nippon Ronen Igakkai Zasshi, 35: 358-362, 1998. (in Japanese)
3. Niitsu N, Nakayama M, Umeda M, et al. Usefulness of THP-COPBLM therapy in elderly patrients with non-Hodgkin's lymphoma. Gan To Kagaku Ryoho, 24: 61-66, 1997.
4. Kitamura K, Takaku F. Pirarubicin, a novel derivative of doxorubicin: THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol, 13 (Suppl 1): S15-19, 1990.
5. Tsukakoshi S. Pirarubicin (THP-adriamycin). Gan To Kagaku Ryoho, 15: 2819-2827, 1998. (in Japanese)
6. Guerci A, Lederlin P, Reyes F, et al. Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-combination chemotherapy regimen. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol, 7: 966-969, 1996.
7. Niitsu N, Umeda M. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III and THP-COPBLM. Eur J Haematol, 63: 337-344, 1999.
8. Aoki S, Tsukada N, Nomoto N, et al. Effect of pirarubicin for elderly patients with malignant lymphoma. J Exp Clin Cancer Res, 17: 465-470, 1998.
9. Kitamura K. Chemotherapy for malignant lymphoma in the elderly - A pilot study of the combination chemotherapy including pirarubicin. Hematol & Oncol, 21: 434-440, 1990.
10. Tsurumi H, Yamada T, Sawada M, et al. Biweekly CHOP or Biweekly THP-COP regimen in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma - A comparison of doxorubicin and pirarubicin: a randomized phase II study. J Cancer Res Clin Oncol, 130: 107-113, 2004.
11. Velasquez WS, Fuller LM, Jagannath S, et al. Stage I and II diffuse large cell lymphomas: Prognostic factors and long-term results with CHOP-bleo and radioitherapy. Blood, 77: 942-947, 1991.
12. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med, 339: 21-26, 1998.
13. Nikkuni K, Aoki S, Tsukada N, et al. A phase II multicenter clinical trial of high-dose bi-weekly THP-COP with G-CSF support (HDBW-TCOP(G)) for non-Hodgkin's lymphoma. Proc Am Soc Hematol, 43: 517-I, 2001 (abstr #571).
14. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol, 16: 2780-2795, 1998.
15. Nakamura K, Sasaki M, Kunitake N, et al. Relapse patterns of localized non-Hodgkin's lymphoma of the head and neck after clinical remission: results of a strict follow-up procedure. Int J Clin Oncol, 6: 302-305, 2001.
16. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol, 17: 1244-1253, 1999.
17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457-481, 1958.
18. Itami J. Radition therapy of localized diffuse large B-cell lymphoma. Nippon Acta Radiologica, 63: 89-92, 2003.
19. Wilder RB, Romaguera JE, Tucker SL, et al. Results with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and predonisone followed by radiotherapy with or without prechemotherapy surgical debulking for patients with bulky, aggressive lymphoma. Cancer, 94: 601-605, 2002.
20. Kamath SS, Marcus RB Jr, Lynch JW, Mendenhall NP. The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys, 44: 563-568, 1999.
21. Connors JM, Klimo P, Fairey RN, Voss N. Brief chemotherapy and involved field radiation therapy for limited stage, histologically aggressive lymphoma. Ann Intern Med, 107: 25-30, 1987.
22. Tondini C, Zanini M, Lombardi F, et al. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas. J Clin Oncol, 11: 720-725, 1993.
23. Miller TP, LeBlanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas; update of the Southwest Oncology Group (SWOG) randomized trial. Blood, 98: 724a-725a, 2001.
24. Glick JH, Kim K, Earle J, et al. An ECOG randomized phase III trial of CHOP vs. CHOP+Radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's Lymphoma. Proceedings of ASCO, 14: 391, 1995.
25. Kitamura K, Takaku F. Pirarubicin, a novel derivative of doxorubicin-THP-COP therapy for non-Hodgkin's lymphoma in the elderly. Am J Clin Oncol, 13 (Suppl 1): S15-19, 1990.
26. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol, 12: 2471-2508, 1994.
27. Niitsu N, Umeda M. Response and adverse drug reactions to combination chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma: comparison of CHOP, COP-BLAM, COP-BLAM III, and THP-COPBLM. Eur J Haematol, 63: 337-344, 1999.
28. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer, 97: 2869-2879, 2003.
29. Tsang RW, Gospodarowicz MK. Management of localized (stage I and II) clinically aggressive lymphomas. Ann Hematol, 80 (Suppl 3): B66-72, 2001.